| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5ecdaa979a95646ef67daeba9a3cd0b |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate |
2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8da29bab7df9086163aa04d2ff00afc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8116303b0bafd6ac82bba8211a1a80f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_691b1e348f559ae1761a8eaa5155962d |
| publicationDate |
2013-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103156860-A |
| titleOfInvention |
Olanzapine composition and preparation method thereof |
| abstract |
The invention provides a composition comprising olanzapine crystalline particles with an average particle size equal to or smaller than 30 [mu]m and a pharmaceutically acceptable carrier. The olanzapine crystalline particles with the average particle size equal to or smaller than 30 [mu]m are basically bioequivalent. The composition can be used for treating mental diseases such as schizophrenia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104887634-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111643506-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111836615-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104523631-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105078893-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113143878-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104887634-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11752100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104523631-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105106141-A |
| priorityDate |
2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |